Astellas Canadian Study Tracks Real-World Zolbetuximab Use in Advanced Gastric Cancer

• Astellas Pharma reported Canadian real-world data showing that a national testing program enabled timely access to zolbetuximab with chemotherapy for eligible patients with advanced stomach or gastroesophageal junction cancer.
• The findings were presented at the ESMO congress in Madrid on Oct. 25, 2026.
• The program linked CLDN18.2 biomarker testing to targeted treatment for patients with CLDN18.2-positive, HER2-negative tumors while public reimbursement was pending.
• Across eight provinces, 63 patients received at least one treatment cycle between May 20, 2025, and Jan. 31, 2026.
• The descriptive study used limited patient-support program data, restricting interpretation of the findings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Astellas Pharma Inc. published the original content used to generate this news brief via CNW (Ref. ID: 202610260900CANADANWCANADAPF_C1060) on October 26, 2026, and is solely responsible for the information contained therein.